EGRF conjugated PEGylated nanographene oxide for targeted chemotherapy and photothermal therapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 23800742.
- Also identified by DOI 10.1016/j.biomaterials.2013.06.007.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Low accumulation of chemotherapeutic agent in tumor tissue and multidrug resistance (MDR) present a major obstacle to curing cancer treatment. Therefore, how to combine several therapeutics in one system is a key issue to overcome the problem. Here, we demonstrate epidermal growth factor receptor (EGFR) antibody-conjugated PEGylated nanographene oxide (PEG-NGO) to carry epirubicin (EPI) for tumor targeting and triple-therapeutics (growth signal blocking, chemotherapy, photothermal therapy) in tumor treatment. This synergistic targeted treatment simultaneously enhances the local drug concentration (6.3-fold) and performs the ultra-efficient tumor suppression to significantly prolong the mice survival (over the course of 50 days).
Medical subject headings
- Antibiotics, Antineoplastic
- Antibodies, Immobilized
- Epirubicin
- ErbB Receptors
- Glioma
- Graphite